STATE STREET CORP
State Street Corporation and affiliate SSGA Funds Management filed Schedule 13G disclosures for Sarepta Therapeutics. State Street reports 8,916,103 shares, 8.4% of the class, with shared voting power of 8,642,126 and shared dispositive power of 8,916,103. SSGA Funds Management reports 6,285,547 shares, 6%.
State Street Corporation (NYSE: STT) disclosed beneficial ownership of 4,985,060 shares of Myriad Genetics, Inc. common stock, representing 5.3% of the class, in a regulatory filing. The shares have shared voting power (4,866,068) and shared dispositive power (4,985,060), with no sole voting or dispositive power reported.
State Street Corporation (NYSE: STT) filed a Schedule 13G reporting beneficial ownership of 24,478,268 shares of Iovance Biotherapeutics, representing 5.5% of the class. The filing attributes shared voting power of 23,483,868 shares and shared dispositive power of 24,478,268 shares, with no sole voting or dispositive power.
Over the past 7 days, alphai's AI scored 7 news stories mentioning STT (STATE STREET CORP). Coverage has skewed bullish: 4 bullish, 3 neutral, and 0 bearish.
Recent STT coverage spans financial news and technology.
In the last 30 days, STT insiders filed 4 SEC Form 4 transactions — no purchases and 4 sales ($5.6M). The most active reporter was Schaefer Elizabeth, SVP, Chief Accounting Officer, with 1 filing. 75% of activity was filed under pre-arranged Rule 10b5-1 plans.
The filing is a new, specific disclosure of State Street’s beneficial ownership stake in SRPT, which can affect perceived shareholder influence and positioning.
The filing signals a new or updated 5.3% stake in Myriad Genetics, which can affect positioning and sentiment around STT’s biotech exposure.
The disclosure is a fresh, primary-source ownership update that can shift perceived institutional positioning in Iovance, but it does not indicate control or immediate operational change.
The lease is a tangible expansion/commitment in Dublin, but it is unlikely to be material to near-term earnings; it may modestly support sentiment around cost discipline and long-term footprint.
New product launch in Australia could modestly improve State Street’s ETF fee opportunity and distribution footprint, but near-term impact is likely limited.
alphai scores every news story that mentions STT with an AI model for sentiment and relevance, and aggregates insider trades from STATE STREET CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
State Street Corporation and affiliate SSGA Funds Management filed Schedule 13G disclosures for Sarepta Therapeutics. State Street reports 8,916,103 shares, 8.4% of the class, with shared voting power of 8,642,126 and shared dispositive power of 8,916,103. SSGA Funds Management reports 6,285,547 shares, 6%.
2 min readState Street Corporation (NYSE: STT) disclosed beneficial ownership of 4,985,060 shares of Myriad Genetics, Inc. common stock, representing 5.3% of the class, in a regulatory filing. The shares have shared voting power (4,866,068) and shared dispositive power (4,985,060), with no sole voting or dispositive power reported.
2 min readState Street Corporation (NYSE: STT) filed a Schedule 13G reporting beneficial ownership of 24,478,268 shares of Iovance Biotherapeutics, representing 5.5% of the class. The filing attributes shared voting power of 23,483,868 shares and shared dispositive power of 24,478,268 shares, with no sole voting or dispositive power.
4 min readState Street Corporation (NYSE:STT) signed a multi-year lease for a new Dublin office at 2 Grand Canal Quay, starting in Q3 2027. It will occupy 80,000 sq. ft across levels 4 to 10. The company cites continued investment in Ireland and notes a 2024 Kilkenny cybersecurity center. Island Capital developed the building.
3 min readState Street Investment Management said it will launch its first active ETFs in Australia with Blackstone. Two fixed-income ETFs, SBSL and SBHI, are scheduled to list on the ASX on 7 August. SBSL targets sub-investment grade floating-rate senior secured bank loans, while SBHI seeks income via dynamic allocation across liquid credit markets.
4 min readST Telemedia Global Data Centres (STT GDC) said it is scaling its Philippine data center capacity toward 128 MW, discussed in a July 30 meeting in Singapore with Philippines DTI Secretary Cristina Roque and STT GDC executives. STT GDC said it recently energized 32 MW at its flagship campus and plans further expansion with Ayala Corp. and Globe, plus renewable power work with Ayala and ACEN.
4 min readPhilippines’ Department of Trade and Industry reaffirmed support for ST Telemedia Global Data Centers (STT GDC) as it expands data center capacity to meet AI and cloud demand. STT GDC targets scaling Philippines capacity toward 128 MW, with 32 MW recently online. DTI Secretary Cristina Roque met leadership in Singapore; expansion backed by Ayala and Globe, with regulatory support via the Board of Investments.
4 min readAnalysts issued new ratings for Riot Platforms (RIOT), State Street (STT) and Arthur J Gallagher & Co (AJG). Bernstein reiterated Buy on RIOT with a $30 target; Morgan Stanley started coverage at Buy with $36. Barclays set Hold on STT at $200. Barclays kept Buy on AJG at $292. Consensus targets were also cited.
3 min readState Street Investment Management launched its first active ETFs in Australia with Blackstone. The ASX listings are set for 7 August: SBSL (AUD Hedged) and SBHI (AUD Hedged). SBSL targets sub-investment grade floating-rate senior secured bank loans; SBHI targets income via dynamic allocation across liquid credit. Both feeder funds invest in existing US ETFs.
3 min readSingtel said it is exploring a Nasdaq-SGX dual listing and a data centre REIT listing, with no decision on timing or structure. It also reappointed KPMG as auditor after KPMG Australia staff shared sensitive Optus information during a Telstra bid. Singtel expects STT GDC deal to close within two months. Singtel shares rose 1.8% to S$4.61.
6 min read
